These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms. Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995 [TBL] [Abstract][Full Text] [Related]
7. Multiple giant succular and fusiform right and left coronary artery aneurysms after early and adequate treatment of atypical kawasaki disease with unusual presentation. Behjati-Ardakani M; Ferdosian F Acta Med Iran; 2014; 52(6):490-2. PubMed ID: 25130161 [TBL] [Abstract][Full Text] [Related]
8. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Wooditch AC; Aronoff SC Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713 [TBL] [Abstract][Full Text] [Related]
9. Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population. Friedman KG; Gauvreau K; Hamaoka-Okamoto A; Tang A; Berry E; Tremoulet AH; Mahavadi VS; Baker A; deFerranti SD; Fulton DR; Burns JC; Newburger JW J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633390 [TBL] [Abstract][Full Text] [Related]
10. Extensive coronary aneurysms with thrombosis in resistant Kawasaki disease. Sivakumar K; Pavithran S Pediatr Cardiol; 2013 Feb; 34(2):444-6. PubMed ID: 22427313 [TBL] [Abstract][Full Text] [Related]
11. [Improving the diagnosis and therapy of Kawasaki disease]. Du JB Zhonghua Er Ke Za Zhi; 2006 May; 44(5):321-3. PubMed ID: 16780704 [No Abstract] [Full Text] [Related]
12. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA; Pediatrics; 2004 Dec; 114(6):1708-33. PubMed ID: 15574639 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA; ; ; ; Circulation; 2004 Oct; 110(17):2747-71. PubMed ID: 15505111 [TBL] [Abstract][Full Text] [Related]
14. Effect of different doses of aspirin on the prognosis of Kawasaki disease. Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316 [TBL] [Abstract][Full Text] [Related]
15. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139 [TBL] [Abstract][Full Text] [Related]
16. Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms. Selamet Tierney ES; Runeckles K; Tremoulet AH; Dahdah N; Portman MA; Mackie AS; Harahsheh AS; Lang SM; Choueiter NF; Li JS; Manlhiot C; Low T; Mathew M; Friedman KG; Raghuveer G; Norozi K; Szmuszkovicz JR; McCrindle BW; J Pediatr; 2022 Jan; 240():164-170.e1. PubMed ID: 34474088 [TBL] [Abstract][Full Text] [Related]
17. Kawasaki disease: a comprehensive review of treatment options. Patel RM; Shulman ST J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. Downie ML; Manlhiot C; Collins TH; Chahal N; Yeung RSM; McCrindle BW Int J Cardiol; 2017 Jun; 236():157-161. PubMed ID: 28089146 [TBL] [Abstract][Full Text] [Related]
19. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Saulsbury FT Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377 [TBL] [Abstract][Full Text] [Related]
20. Reevaluation of the efficacy of intravenous gammaglobulin in the prevention and treatment of coronary artery lesion in Kawasaki disease. Qin L; Saumu MT; Wang H; Shi H; Hu X; Cheng P J Huazhong Univ Sci Technolog Med Sci; 2005; 25(3):348-50, 370. PubMed ID: 16201293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]